IP Library Patent Application 12471983
Patent Application
App. No. 12/471,983

ISOLATED MODIFIED HUMAN CHORIONIC GONADOTROPIN PROTEINS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/471,983
Abstract

Compositions and methods based on mutant Cystine Knot Growth Factors (CKGFs) comprising amino acid substitutions relative to the wild type hormone/growth factor. Mutated glycoprotein hormones, including thyroid stimulating hormone (TSH) and chorionic gonadotropin (CG) are disclosed as exemplary mutant CKGFs. Mutant TSH heterodimers and hCH heterodimers possessed modified bioactivities, including superagonist activity. Accordingly, the present invention provides methods for using mutant CKGFs, CKGF analogs, fragments, and derivatives thereof for treating or preventing diseases. Pharmaceutical and diagnostic compositions, methods of using mutant TSH heterodimers and TSH analogs with utility for treatment and prevention of metabolic and reproductive diseases are also provided.

Claims (19)

1 . A human glycoprotein hormone family protein comprising at least one electrostatic charge altering mutation in a β hairpin loop structure, wherein said mutation results in said human glycoprotein hormone family protein having increased bioactivity.

2 . The human glycoprotein hormone family protein of claim 1 , wherein the protein is the human chorionic gonadotropin (CG) β subunit.

3 . The human glycoprotein hormone family protein of claim 2 , wherein the at least one electrostatic charge altering mutation is in the L1 β hairpin loop at a position selected from the group consisting of positions 1-37.

4 . The human glycoprotein hormone family protein of claim 3 , wherein the at least one electrostatic charge altering mutation comprises at least one basic residue introducing mutation selected from the group consisting of S1B, P4B, L5B, P7B, R8B, R10B, P11B, I12B, N13B, A14B, T15B, L16B, A17B, V18B, G22B, P24B, V25B, I27B, T28B, V29B, N30B, T31B, T32B, I33B, A35B, G36B, and Y37B, wherein B is a basic amino acid residue.

5 . The human glycoprotein hormone family protein of claim 2 , wherein the at least one electrostatic charge altering mutation is in the L3 β hairpin loop at a position selected from the group consisting of positions 58-87.

6 . The human glycoprotein hormone family protein of claim 5 , wherein the at least one electrostatic charge altering mutation comprises at least one basic residue introducing mutation selected from the group consisting of N58B, Y59B, V62B, F64B, S66B, I67B, L69B, P70B, G71B, P73B, G75B, V76B, N77B, P78B, G79B, V80B, S81B, Y82B, A83B, V84B, A85B, L86B, and S87B, wherein B is a basic amino acid residue.

7 . The human glycoprotein hormone family protein of claim 2 , wherein the subunit is linked to another cystine knot growth factor monomer.

8 . The human glycoprotein hormone family protein of claim 1 , wherein the protein is the human luteinizing hormone (LH) β subunit.

9 . The human glycoprotein hormone family protein of claim 8 , wherein the at least one electrostatic charge altering mutation is in the L1 β hairpin loop at a position selected from the group consisting of positions 1-33.

10 . The human glycoprotein hormone family protein of claim 9 , wherein the at least one electrostatic charge altering mutation comprises at least one basic residue introducing mutation selected from the group consisting of W8B, P11B, I12B, N13B, A14B, I15B, L16B, A17B, V18B, G22B, P24B, V25B, I27B, T28B, V29B, N30B, T31B, T32B, and 133B, wherein B is a basic amino acid residue.

11 . The human glycoprotein hormone family protein of claim 8 , wherein the at least one electrostatic charge altering mutation is in the L3 β hairpin loop at a position selected from the group consisting of positions 58-87.

12 . The human glycoprotein hormone family protein of claim 8 , wherein the at least one electrostatic charge altering mutation comprises at least one basic residue introducing mutation selected from the group consisting of N58B, Y59B, V62B, F64B, S66B, I67B, L69B, P70B, G71B, P73B, G75B, V76B, N77B, P78B, G79B, V79B, V80B, S81B, Y82B, A83B, V84B, A85B, L86B, and S87B, wherein B is a basic amino acid residue.

13 . The human glycoprotein hormone family protein of claim 8 , wherein the β subunit is linked to another cystine knot growth factor monomer.

14 . The human glycoprotein hormone family protein of claim 1 , wherein the protein is the human follicle stimulating hormone (FSH) β subunit.

15 . The human glycoprotein hormone family protein of claim 14 , wherein the at least one electrostatic charge altering mutation is in the L1 β hairpin loop at a position selected from the group consisting of positions 4-27.

16 . The human glycoprotein hormone family protein of claim 15 , wherein the at least one electrostatic charge altering mutation comprises at least one basic residue introducing mutation selected from the group consisting of L5B, T6B, N7B, I8B, T9B, I10B, A11B, I12B, F19B, I21B, S22B, I23B, N24B, T25B, T26B, and W27B, wherein B is a basic amino acid residue.

17 . The human glycoprotein hormone family protein of claim 14 , wherein the at least one electrostatic charge altering mutation is in the L3 β hairpin loop at a position selected from the group consisting of positions 65-81.

18 . The human glycoprotein hormone family protein of claim 17 , wherein the at least one electrostatic charge altering mutation comprises at least one basic residue introducing mutation selected from the group consisting of A65B, A68B, S70B, L71B, Y72B, T73B, Y74B, P75B, V76B, A77B, T78B, and Q79B, wherein B is a basic amino acid residue.

19 . The human glycoprotein hormone family protein of claim 14 , wherein the β subunit is linked to another cystine knot growth factor monomer.

Assignments (3)
ASSIGNMENT OF ASSIGNEES' SECURITY INTEREST AT REEL 028069 AND FRAME 0928 Recorded Jul 10, 2013
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II (CAYMAN) L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.
To: PALADIN LABS INC.
Reel/Frame 030783/0167 →
SECURITY AGREEMENT Recorded Apr 18, 2012
From: BIONICHE LIFE SCIENCES INC.
To: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II (CAYMAN) L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.
Reel/Frame 028069/0928 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2009
From: WEINTRAUB, BRUCE D.; SZKUDLINSKI, MARIUSZ W.
To: UNIVERSITY OF MARYLAND, BALTIMORE
Reel/Frame 022820/0166 →